Accelerating China's innovation efficiency and global drug innovation is the core value of CPIC 2026.
Antibody drugs and ADCs constitute the core part of China's new drug exports and are also important components of the CPIC 2026 conference. The complete schedule of the "Global Innovation Special Session on Antibody and ADC Drugs" has been updated today. The expert lineup can be described as luxurious, and the special session brings together the founders and presidents of leading antibody and ADC companies such as Yingen Biotechnology, Corning Jerry's, Yilian Biotechnology, Yiming Anke, Sansheng Guojian, and Lepu Biotechnology. It focuses on core issues such as global innovation strategies, differentiated clinical development, global value reconstruction of industrial chains, and next-generation technology platforms for in-depth discussions, presenting a feast of ideas from molecular design to global markets.
From July 22nd to 24th, at the Shanghai National Convention and Exhibition Center, we look forward to exploring the global innovation path of antibodies and ADC drugs with you.

Register on the 'Code'
 

Special Session Schedule
Co-organizer: Altruist Biologics

13:30-13:45　Global Innovation Strategy of DualityBio
John Zhu：Chairman, DualityBio

13:45-14:00　Global Collaboration Opportunities and Clinical Progress of Alphamab Oncology's Product Pipeline
Ting Xu：Chairman & President, Alphamab Oncology

14:00-14:15    Restructuring the Value Chain of Antibody andADCs from Local to Global
Cuiling Song：Senior Director of Applications & Products, BioLink

14:15-14:30　Differentiated Clinical Strategies for ADC Global Expansion and Development
Tongtong Xue：CEO, MediLink Therapeutics

14:30-14:45　Global Collaboration Opportunities and Clinical Progress of ImmuneOnco's Product Pipeline
Wenzhi Tian：Founder & Chairman, ImmuneOnco Biopharmaceuticals

14:45-15:00　Beyond Supply: Innovative Toolchains to Systematically Accelerate ADC Development
Xiaojing An：Dean of Sino Biological Innovation Research Institute

15:00-15:15　Innovation Strategy of Lepu Biopharma
Ziye Sui：CEO, Lepu Biopharma

15:15-15:30　Innovation Strategy of 3SBio
Yanli Liu：General Manager, 3SBio

15:30-15:45　Antibody Innovation Strategy of Affinity Biopharma
Junli Zhang：Senior Vice President, ADC BU Head and MFG Sites Head,Zencore Biologics

15:45-16:00　Everest Medicines’ Antibody Innovation Strategy
Rogers Luo：CEO，Everest Medicines

16:00-16:15    Innovation Strategy of Mabwell
Ke Hu：Senior Vice President, Mabwell

16:15-16:30　Precision Modeling Empowers a New Paradigm in Drug R&D: Application Value of Fully Humanized Mouse Models in Preclinical Research
Yuan  Dong：R&D Director, China, Genovo Biotech

16:30-16:45　A Global Perspective on ADC Development
Chen Liu：Founder, President & Co-CMO, Affinity Biopharma

16:45-17:00　AI-Driven Precision and Scalability Empowering Next-Generation Dual-Payload ADCs
Yi Yang：CSO, Biocytogen

17:00-17:15　Global Development Strategy of Transcenta Holding's Antibody Drugs
Xueming Qian：CEO, Transcenta Holding

17:15-17:30　Digital-Intelligence Integration: Reconstructing Cell Culture Media and Bioprocess Development
Max Wang：CEO, MediumBank